Medicure Stock Performance
| MCUJF Stock | USD 0.70 0.02 2.94% |
The company secures a Beta (Market Risk) of 2.56, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Medicure will likely underperform. At this point, Medicure has a negative expected return of -0.12%. Please make sure to verify Medicure's jensen alpha and the relationship between the potential upside and period momentum indicator , to decide if Medicure performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Medicure has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's forward-looking indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 2.7 M | |
| Total Cashflows From Investing Activities | -2.7 M |
Medicure |
Medicure Relative Risk vs. Return Landscape
If you would invest 80.00 in Medicure on September 1, 2024 and sell it today you would lose (10.00) from holding Medicure or give up 12.5% of portfolio value over 90 days. Medicure is currently producing negative expected returns and takes up 4.4209% volatility of returns over 90 trading days. Put another way, 39% of traded pink sheets are less volatile than Medicure, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Medicure Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medicure's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Medicure, and traders can use it to determine the average amount a Medicure's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.026
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MCUJF |
Estimated Market Risk
| 4.42 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medicure is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medicure by adding Medicure to a well-diversified portfolio.
Medicure Fundamentals Growth
Medicure Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Medicure, and Medicure fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medicure Pink Sheet performance.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.021 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 5.67 M | |||
| Shares Outstanding | 10.25 M | |||
| Price To Earning | 11.45 X | |||
| Price To Book | 0.57 X | |||
| Price To Sales | 0.37 X | |||
| Revenue | 21.74 M | |||
| EBITDA | 2.42 M | |||
| Cash And Equivalents | 4.83 M | |||
| Cash Per Share | 0.47 X | |||
| Total Debt | 1.02 M | |||
| Debt To Equity | 0.05 % | |||
| Book Value Per Share | 2.04 X | |||
| Cash Flow From Operations | 3.99 M | |||
| Earnings Per Share | 0.21 X | |||
| Total Asset | 28.41 M | |||
| Retained Earnings | (89.95 M) | |||
| Current Asset | 12.56 M | |||
| Current Liabilities | 7.45 M | |||
About Medicure Performance
By analyzing Medicure's fundamental ratios, stakeholders can gain valuable insights into Medicure's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Medicure has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medicure has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada. Medicure is traded on OTC Exchange in the United States.Things to note about Medicure performance evaluation
Checking the ongoing alerts about Medicure for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Medicure help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medicure generated a negative expected return over the last 90 days | |
| Medicure has some characteristics of a very speculative penny stock | |
| Medicure has high historical volatility and very poor performance | |
| The company reported the revenue of 21.74 M. Net Loss for the year was (727 K) with profit before overhead, payroll, taxes, and interest of 12.71 M. | |
| About 27.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Medicure's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medicure's stock is overvalued or undervalued compared to its peers.
- Examining Medicure's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medicure's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medicure's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medicure's pink sheet. These opinions can provide insight into Medicure's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Medicure Pink Sheet analysis
When running Medicure's price analysis, check to measure Medicure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicure is operating at the current time. Most of Medicure's value examination focuses on studying past and present price action to predict the probability of Medicure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicure's price. Additionally, you may evaluate how the addition of Medicure to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |